France Primary Hyperoxaluria (PH) Therapeutics Market Report 2022-2030

France Primary Hyperoxaluria (PH) Therapeutics Market Analysis

$ 3999

The France Primary Hyperoxaluria (PH) Therapeutics market was valued at $XX Bn in 2022 and is estimated to expand at a CAGR of 3.8% from 2022 to 2030 and will reach $XX Bn in 2030. One of the main reasons propelling the growth of this market is increase in awareness, aging population. The market is segmented by diagnostic method, by treatment, by type. Some key players in this market Sanofi Genzyme, Ox Thera, Dicerna Pharmaceuticals, AGC Biologics, Sernova among others.

ID: IN10FRPH507 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Nandini Shah

Buy Now

France Primary Hyperoxaluria (PH) Therapeutics Market Executive Summary

The France Primary Hyperoxaluria (PH) Therapeutics market was valued at $XX Bn in 2022 and is estimated to expand at a CAGR of 3.8% from 2022 to 2030 and will reach $XX Bn in 2030. Primary hyperoxaluria is an uncommon hereditary condition that alters how the body metabolises some amino acids. As a result, the body may begin to accumulate oxalate, which can harm the kidneys, bones, and other organs. Chronic and progressing primary hyperoxaluria can cause end-stage renal failure and other life-threatening consequences.

Market Dynamics

Market Growth Drivers

The prevalence of primary hyperoxaluria is increasing worldwide, including in France. This is due to a combination of factors, including better diagnosis, increased awareness, and improvements in genetic testing. As the prevalence of the disease increases, the demand for treatments is also likely to increase, which could drive growth in the market. There is ongoing research and development in the field of primary hyperoxaluria, with several companies developing new treatments for the disease. This includes both drug therapies and cell-based therapies. As these new treatments become available, they may drive growth in the market. The French regulatory authorities are supportive of the development of treatments for rare diseases, including primary hyperoxaluria. This support can include expedited review processes, tax incentives, and other forms of support. This can encourage companies to invest in the development of treatments for the disease, which could drive growth in the market. There are patient advocacy groups in France that are working to raise awareness of primary hyperoxaluria and to support patients with the disease. These groups can be powerful advocates for the development of new treatments, and they may be able to drive demand for these treatments in the market.

Market Restraints

Primary hyperoxaluria is a rare disease, which means that the patient population is limited. This can make it difficult for companies to develop and market treatments for the disease, as the market size may be relatively small. Treatments for primary hyperoxaluria can be expensive, which can make them inaccessible to some patients. This can be a significant barrier to growth in the market, as patients may not be able to afford the treatments that are available. Primary hyperoxaluria is not well known among the general public or even among some healthcare providers. This can make it difficult for patients to receive a timely and accurate diagnosis, and it can make it difficult for companies to market their treatments effectively. While the French regulatory authorities are generally supportive of the development of treatments for rare diseases, there can still be regulatory challenges that must be overcome. These can include issues related to clinical trial design, manufacturing, and pricing. There are already some treatments available for primary hyperoxaluria, including dietary interventions, medication, and kidney transplantation. This can make it difficult for new treatments to gain traction in the market, as they may be competing with existing treatments that are well-established and widely used.

Competitive Landscape

Key Players

Sanofi Genzyme
Ox Thera
Dicerna Pharmaceuticals
AGC Biologics
Sernova

Healthcare Policies and Regulatory Landscape

France has a well-established healthcare policy and regulatory landscape that supports the development and commercialization of treatments for rare diseases, including primary hyperoxaluria.

Primary hyperoxaluria is considered a rare disease, and as such, treatments for the disease may be eligible for orphan drug designation in France. This designation provides certain benefits, including tax incentives and expedited review processes.

In France, treatments for primary hyperoxaluria must be authorized by the French National Agency for Medicines and Health Products Safety (ANSM) before they can be marketed. The ANSM reviews clinical trial data and other evidence to ensure the safety and efficacy of treatments before granting marketing authorization. France has a universal healthcare system that provides access to healthcare services and treatments for all residents. This includes access to treatments for rare diseases such as primary hyperoxaluria. However, the high cost of some treatments can be a barrier to access for some patients.

Reimbursement Scenario

The HAS (Higher Authority of Health, Haute Autorité de santé) evaluates the clinical effectiveness of treatments for primary hyperoxaluria based on clinical trial data and other evidence. Treatments that are shown to be effective in reducing the progression of the disease and improving patient outcomes are more likely to be reimbursed. The HAS also evaluates the cost-effectiveness of treatments for primary hyperoxaluria. Treatments that provide a significant clinical benefit at a reasonable cost are more likely to be reimbursed. Considering the size of the patient population and the burden of the disease when making reimbursement decisions. Treatments for rare diseases such as primary hyperoxaluria may be reimbursed at a higher rate to ensure that patients have access to effective treatments.

Overall, reimbursement for treatments for primary hyperoxaluria in France is generally favorable, with a focus on providing access to effective treatments for patients with rare diseases.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Primary Hyperoxaluria (PH) Therapeutics Market Segmentation

By Diagnostic method

Blood tests & Urine tests
Stone analysis
X-ray Examination
CT scanning & MRI
Biopsy
Molecular genetic testing
DNA Testing

By Treatment

Dietary
Lifestyle
Drug
Kidney Stone Management
Dialysis
Kidney/liver transplant

By Type

Primary Hyperoxaluria Type I
Primary Hyperoxaluria Type II
Primary Hyperoxaluria Type III

Insights10 will provide you with the reports within 10 key parameters which are:

Market Overview
Market Growth Drivers & Restraints
Epidemiology of Disease Type
Market Segmentation
Market Share
Competitive Landscape
Key Company Profiles
Healthcare Policies & Regulatory Framework
Reimbursement Scenario
Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

Establishing market drivers and trends
Analyzing the regulatory landscape to understand future growth
Market Segment based analysis to obtain revenue/volume
Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.